Picture of 4D Molecular Therapeutics logo

FDMT — 4D Molecular Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapMomentum Trap

4D Molecular Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

4D Molecular Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
  • 4D Molecular Therapeutics Inc FDMT.OQ reported a quarterly adjusted loss of $1.08​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of $-1.01. The mean expectation of eleven analysts for the quarter was for a loss of $1.05 per share. Wall Street expected results to range from $-1.10 to -99 cents per share.

  • Revenue rose 4,505.6% to $4.15 million from a year ago; analysts expected $2.70 million.

  • 4D Molecular Therapeutics Inc's reported EPS for the quarter was a loss of $1.08​.

  • The company reported a quarterly loss of $78.06 million.

  • 4D Molecular Therapeutics Inc shares had fallen by 9.2% this quarter and gained 73.2% so far this year.

FORECAST CHANGES

  • The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.​

  • In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

  • Wall Street's median 12-month price target for 4D Molecular Therapeutics Inc is $28.00, about 53.6% above its last closing price of $12.99

This summary was machine generated from LSEG data November 12 at 10:55 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING

ESTIMATE

ACTUAL

BEAT, MET, MISSED

Sep. 30 2026

-1.05

-1.08

Missed

Jun. 30 2026

-1.02

-1.04

Missed

Mar. 31 2026

-0.99

-1.01

Missed

Dec. 31 2025

-0.76

0.43

Beat

Recent news on 4D Molecular Therapeutics

See all news